Author
Listed:
- Anna Chudek
(Health Promotion and Obesity Management Unit, Department of Pathophysiology, Faculty of Medical Sciences in Katowice, Medical University of Silesia in Katowice, 40-752 Katowice, Poland)
- Przemysław Kotyla
(Department of Internal Medicine, Rheumatology and Clinical Immunology, Faculty of Medical Sciences in Katowice, Medical University of Silesia in Katowice, 40-635 Katowice, Poland)
- Małgorzata Mossakowska
(Study on Ageing and Longevity, International Institute of Molecular and Cell Biology, 02-109 Warsaw, Poland)
- Tomasz Grodzicki
(Department of Internal Medicine and Gerontology, Jagiellonian University Medical College, 31-531 Krakow, Poland)
- Tomasz Zdrojewski
(Division of Preventive Medicine and Education, Medical University of Gdansk, 80-211 Gdansk, Poland)
- Magdalena Olszanecka-Glinianowicz
(Health Promotion and Obesity Management Unit, Department of Pathophysiology, Faculty of Medical Sciences in Katowice, Medical University of Silesia in Katowice, 40-752 Katowice, Poland)
- Jerzy Chudek
(Department of Internal Medicine and Oncological Chemotherapy, Medical University of Silesia, 40-029 Katowice, Poland)
- Aleksander J. Owczarek
(Health Promotion and Obesity Management Unit, Department of Pathophysiology, Faculty of Medical Sciences in Katowice, Medical University of Silesia in Katowice, 40-752 Katowice, Poland)
Abstract
Little is known about the occurrence of antibodies in older subjects. We analyzed the prevalence of anticitrullinated protein antibodies (anti-CCP) in a representative cohort of Polish older adults, participants of PolSenior substudy. Randomly selected 1537 serum samples of community-dwelling participants aged 65 and over. Questionnaires were completed by qualified interviewers and laboratory assessments served as a database for this analysis. The frequency of anti-CCP seropositivity (N = 50) was estimated at 3.25% (95% CI: 2.45–4.30%), being higher among women—4.05% (2.83–5.73%) than men—2.41% (1.48–3.86%). The frequency of anti-CCP seropositivity was decreasing with age from 4.29% in aged 65–74 years and 4.07% in 70–84 years to 1.50% in aged 85 years or above ( p < 0.05). Hypoalbuminemia, inflammatory status (C-reactive protein >10 mg/dL or interleukin-6 ≥10 pg/mL), and female gender were associated with increased, while age ≥85 years with decreased risk of seropositivity. Multivariable logistic regression revealed that hypoalbuminemia, inflammatory status, and age ≥85 years were independently associated factors of anti-CCP seropositivity. The decreased frequency of anti-CCP seropositivity in the oldest old suggests shorter survival of the seropositive individuals who developed rheumatoid arthritis. It seems that low symptomatic RA remains frequently undiagnosed in older subjects.
Suggested Citation
Anna Chudek & Przemysław Kotyla & Małgorzata Mossakowska & Tomasz Grodzicki & Tomasz Zdrojewski & Magdalena Olszanecka-Glinianowicz & Jerzy Chudek & Aleksander J. Owczarek, 2022.
"The Prevalence of Anticitrullinated Protein Antibodies in Older Poles—Results from a Population-Based PolSenior Study,"
IJERPH, MDPI, vol. 19(21), pages 1-12, October.
Handle:
RePEc:gam:jijerp:v:19:y:2022:i:21:p:14216-:d:958498
Download full text from publisher
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.
- Sanja Zuzic Furlan & Doris Rusic & Josko Bozic & Mirjana Rumboldt & Zvonko Rumboldt & Marko Rada & Marion Tomicic, 2021.
"How Are We Managing Patients with Hyperuricemia and Gout: A Cross Sectional Study Assessing Knowledge and Attitudes of Primary Care Physicians?,"
IJERPH, MDPI, vol. 18(3), pages 1-11, January.
- Sidsel Dan Hull & Marianne Welzel Andersen & Jessica Bengtsson & Nils Skovgaard & Marie Balslev Backe & Michael Lynge Pedersen, 2022.
"Prevalence of Patients Receiving Urate-Lowering Medicine in Greenland and Denmark: A Cross-Sectional Case–Control Study,"
IJERPH, MDPI, vol. 19(12), pages 1-8, June.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:19:y:2022:i:21:p:14216-:d:958498. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.